IP Library › Granted Patent US 12,708,664
Granted Patent B2
US 12,708,664 · App. 17/608,637 · Granted Aug 18, 2026

Methods of treating paraproteinemic neuropathy with anti-C2 antibodies

Inventors: Christophe Blanchetot (Ghent, BE); Kevin Budding (Vleuten, NL); Erik Hack (Diemen, NL); Karen Silence (Ghent, BE); Inge Van De Walle (Ghent, BE); Ludo Van Der Pol (Amersfoort, NL); Peter Boross (Utrecht, NL)
Assignee: argenx BV
A61K39/3955A61P25/02C07K16/18C07K16/40C07K2317/24C07K2317/56C07K2317/565C12N9/6408C12Y304/21043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,708,664
App. No.
17/608,637
Filed
Nov 3, 2021
Granted
Aug 18, 2026
Kind
B2
Art Unit
1674
USPC
424/133.1
Abstract

The present invention relates to a method of treating a paraproteinemic neuropathy in a subject by administering to the subject an antagonist of the complement system. The antagonist inhibits the complement system upstream of complement factor C5. More specifically, the antagonist may be an antibody or an antigen-binding fragment thereof that blocks or inhibits the complement system by inhibiting the C2b domain of complement factor C2. The paraproteinemic neuropathies that may be treated include, in particular, multifocal motor neuropathy (MMN), chronic inflammatory demyelinating polyneuropathy (CIDP), and Guillain-Barre syndrome (GBS).

Claims (11)

1 . A method of treating a paraproteinemic neuropathy in a subject, the method comprising administering to the subject an anti-C2 antibody or antigen-binding fragment thereof comprising a heavy chain variable domain (VH) and a light chain variable domain (VL), wherein the VH comprises the amino acid sequence of SEQ ID NO: 8, and the VL comprises complementarity determining regions LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 7, 6, and 5, respectively.

2 . The method of claim 1 , wherein the anti-C2 antibody or antigen-binding fragment thereof inhibits the classical complement pathway and/or the lectin complement pathway.

3 . The method of claim 1 , wherein the paraproteinemic neuropathy is a demyelinating neuropathy.

4 . The method of claim 1 , wherein the paraproteinemic neuropathy is characterised by the presence of autoantibodies, optionally wherein the autoantibodies target a neural antigen.

5 . The method of claim 4 , wherein the neural antigen is a ganglioside or myelin-associated glycoprotein (MAG), optionally wherein the ganglioside is selected from the group consisting of GM1, GM1b, GM2, GM3, GD1a, GD1b, GD2, GD3, GT1a, GT1b, GT3, and GQ1b.

6 . The method of claim 1 , wherein the paraproteinemic neuropathy is selected from the group consisting of: multifocal motor neuropathy (MMN), chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre syndrome (GBS), Miller Fisher syndrome, acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy (AMSAN), chronic ataxic neuropathy-ophthalmoplegia-IgM paraprotein-cold agglutinins-disialosyl antibodies (CANOMAD) syndrome, distal acquired demyelinating symmetric (DADS) neuropathy, monoclonal gammopathy associated peripheral neuropathy, anti-MAG peripheral neuropathy, and POEMS syndrome.

7 . The method of claim 1 , wherein the VL comprises the amino acid sequence of SEQ ID NO: 9.

8 . The method of claim 1 , wherein the antibody or antigen-binding fragment comprises a human IgG heavy chain constant domain.

9 . The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 16 and a light chain comprising the amino acid sequence of SEQ ID NO: 20.

10 . The method of claim 1 , further comprising administering intravenous immunoglobulin to the subject.

11 . The method of claim 1 , further comprising administering rituximab to the subject.

Assignments (2)
CHANGE OF NAME Recorded Apr 8, 2022
From: ARGENX BVBA
To: ARGENX BV
Reel/Frame 059539/0878 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2022
From: BLANCHETOT, CHRISTOPHE; BUDDING, KEVIN; HACK, ERIK; SILENCE, KAREN; VAN DE WALLE, INGE; VAN DER POL, LUDO; BOROSS, PETER
To: ARGENX BVBA
Reel/Frame 058633/0507 →
Priority Claims (1)
GB 1907153 · May 21, 2019 · national
Continuity (1)
Related Publication 20250066460A1 · Feb 27, 2025
References Cited (91)
US 6998468B2 · Fung et al. · 2006 [cited by applicant]
US 7927592B2 · Fung et al. · 2011 [cited by applicant]
US 8163881B2 · Ober · 2012 [cited by applicant]
US 8221756B2 · Fung et al. · 2012 [cited by applicant]
US 8834871B2 · Ober · 2014 [cited by applicant]
US 8911735B2 · Fung et al. · 2014 [cited by applicant]
US 9944717B2 · Hack et al. · 2018 [cited by applicant]
US 10717785B2 · Hack et al. · 2020 [cited by applicant]
US 11161900B2 · Blanchetot et al. · 2021 [cited by applicant]
US 11591386B2 · Blanchetot et al. · 2023 [cited by applicant]
US 11708403B2 · Blanchetot et al. · 2023 [cited by applicant]
US 20110104156A1 · Christadoss et al. · 2011 [cited by applicant]
US 20150064195A1 · Kupper et al. · 2015 [cited by applicant]
US 20150064395A1 · Kupper et al. · 2015 [cited by applicant]
US 20160108134A1 · Hack et al. · 2016 [cited by applicant]
US 20180319895A1 · Hack et al. · 2018 [cited by applicant]
US 20200239554A1 · Blanchetot et al. · 2020 [cited by applicant]
US 20220119509A1 · Blanchetot et al. · 2022 [cited by applicant]
US 20220267424A1 · Blanchetot et al. · 2022 [cited by applicant]
US 20240002484A1 · Blanchetot et al. · 2024 [cited by applicant]
CA 3055781A1 · 2018 [cited by applicant]
EP 1265929A1 · 2002 [cited by applicant]
JP 2018534246A · 2018 [cited by applicant]
WO WO2001070818A1 · 2001 [cited by applicant]
WO WO2008044928A1 · 2008 [cited by applicant]
WO WO2010056399A1 · 2010 [cited by applicant]
WO WO2013036778A2 · 2013 [cited by applicant]
WO WO2014096958A1 · 2014 [cited by applicant]
WO WO2014186599A2 · 2014 [cited by applicant]
WO WO2014189378A1 · 2014 [cited by applicant]
WO WO2015089368A2 · 2015 [cited by applicant]
WO WO2016073685A1 · 2016 [cited by applicant]
WO WO2017046172A1 · 2017 [cited by applicant]
WO WO2017091719A1 · 2017 [cited by applicant]
WO WO2017129737A1 · 2017 [cited by applicant]
WO WO2017196960A1 · 2017 [cited by applicant]
WO WO2019089922A1 · 2019 [cited by applicant]
WO WO2020121282A1 · 2020 [cited by applicant]
WO 2020234432A1 · 2020 [cited by applicant]
Benjamini et al, 1991. Immunology: A Short Course, 2nd edition, p. 40 only. [cited by examiner]
Bentley et al, 1986. Biochem J. 239:339-345. [cited by examiner]
Ferrara et al (2015. mAbs. 7(1): 32-41). [cited by examiner]
Jinka et al, 2014. Curr Treat Options Neurol. 16:269. [cited by examiner]
U.S. Appl. No. 14/892,850 2016/0108134 U.S. Pat. No. 9,944,717, filed May 22, 2014 Apr. 21, 2016 Apr. 17, 2018, Cornelis Erik Hack. [cited by applicant]
U.S. Appl. No. 15/903,810 2018/0319895 U.S. Pat. No. 10,717,785, filed Feb. 23, 2018 Nov. 8, 2018 Jul. 21, 2020, Cornelis Erik Hack. [cited by applicant]
U.S. Appl. No. 17/608,637, filed Nov. 3, 2021, Christophe Blanchetot. [cited by applicant]
U.S. Appl. No. 16/714,264 2020/0239554 U.S. Pat. No. 11,161,900, filed Dec. 13, 2019 Jul. 30, 2020 Nov. 2, 2021, Christophe Blanchetot. [cited by applicant]
U.S. Appl. No. 17/491,656, filed Oct. 1, 2021, Christophe Blanchetot. [cited by applicant]
U.S. Appl. No. 17/572,518, filed Jan. 10, 2022, Christophe Blanchetot. [cited by applicant]
Lin et al., “Improved affinity of a chicken single-chain antibody to avian infectious bronchitis virus by site-directed mutagenesis of complementarity-determining region H3”, African Journal of Biotechnology, Dec. 12, 2… [cited by applicant]
McCarthy et al., “Altering the fine specificity of an anti-Legionella single chain antibody by a single amino acid insertion”, Journal of Immunological Methods, 2001, 251(1-2):137-149. [cited by applicant]
Paul, “Fundamental Immunology”, under the heading “Fv Structure and Diversity in Three Dimensions”, 1993, 3rd Edition, pp. 292-295. [cited by applicant]
International Preliminary Report on Patentability received for PCT Application No. PCT/NL2014/050327, mailed on Dec. 3, 2015, 8 pages. [cited by applicant]
“Argenx announces expansion of its pipeline with addition of complement-targeted ARGX-117 for treatment of severe auto-immune diseases”, argenx SE, Mar. 22, 2018, Retrieved from url: ,https://www.globenewswire.com/news-… [cited by applicant]
“Argenx Annual Report 2018”, Mar. 26, 2019, Retrieved from url: <https://argenx.com/sites/default/files/media-documents/argenx-annual-report-2018-final.pdf>. [cited by applicant]
Anderson, C.M., et al., “A Monoclonal Antibody Against Human Complement Component C2,” Biochemical Society Transactions, Portland Press Ltd, BG, vol. 15, No. 4, pp. 660-661, Jan. 1, 1987. [cited by applicant]
Arlaud et al., “The atypical serine proteases of the complement system”, Advanced Immunology, 1998, vol. 69, pp. 249-307. [cited by applicant]
Cats et al., “Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy”, Neurology, 2010, pp. 818-825. [cited by applicant]
Colman, “Effects of amino acid sequence changes on antibody-antigen interactions”, Research Immunology, vol. 145; pp. 33-36, 1994. [cited by applicant]
Combined Search and Examination Report for GB Patent Application No. 1907153.9, mailed Nov. 29, 2019. [cited by applicant]
Edimara et al., “Applying complement therapeutics to Rare Diseases”, Clinical Immunology, 2015, 161: 225-240. [cited by applicant]
Hahn et al. “A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy”, J Peripher Nerv Syst, Dec. 2013, 18(4): 321-330. [cited by applicant]
Heinz, H.P., et al., “Monoclonal Antibodies Against Components of the Classical Pathway of Complement,” Complement and Inflammation, Karger Basel, CH, vol. 6, No. 3, pp. 166-174, Jan. 1, 1989. [cited by applicant]
Horiuchi et al., “Site-directed mutagenesis of the region around Cys-241 of complement component C2. Evidence for a C4b binding site”, Journal of Immunology, 1991, vol. 147, No. 2, pp. 584-589. [cited by applicant]
Huda, R., et al., “Complement C2 siRNA Mediated Therapy of Myasthenia Gravis in Mice,” Journal of Autoimmunity, vol. 42, pp. 94-104, May 1, 2013. [cited by applicant]
Igawa et al., “Reduced elimination of IgG antibodies by engineering variable region”, Protein Engineering, Design and Selection, May 2010, vol. 23, Issue 5, pp. 385-392. [cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/NL2014/050327, dated Oct. 1, 2014. [cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/EP2020/064234, dated Oct. 26, 2020. [cited by applicant]
International Search Report and Written Opinion in related PCT Application No. PCT/IB2019/060802, dated Mar. 31, 2020. [cited by applicant]
Jackson, et al., “In Vitro Antibody Maturation,” Journal of Immunology, 1995, 154: 3310-3319. [cited by applicant]
Krishnan et al., “The crystal structure of C2a, the catalytic fragment of classical pathway C3 and C5 convertase of human complement”, Journal of Molecular Biology, 2007, vol. 367, No. 1, pp. 224-233. [cited by applicant]
Krishnan, et al., “The Structure of C2b, a Fragment of Complement Component C2 Produced during C3 Convertase Formation,” Acta Crystallography, D65: 266-274, 2009. [cited by applicant]
Lansita et al., “Nonclinical Development of ANX005: A Humanized Anti-Clq Antibody for Treatment of Autoimmune and Neurodegenerative diseases” Int'l Journal of Toxicology, 2017, 36(6): 449-462. [cited by applicant]
Mauriello et al. “A novel peptide inhibitor of classical and lectin complement activation including ABO incompatibility”, Mol Immunol, Jan. 2013, 53(0): 132-139. [cited by applicant]
McGonigal et al., “Clq-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy”, Acta Neuropathologica Communications, 2016, 4(23): 1-16. [cited by applicant]
Milder et al., “Structure of complement component C2A: implications for convertase formation and substrate binding”, Structure, 2006, vol. 14, No. 10, pp. 1587-1597. [cited by applicant]
Norman et al., “Three-dimensional structure of a complement control protein module in solution”, Journal of Molecular Biology, Jun. 20, 1991, vol. 219, No. 4, pp. 717-725. [cited by applicant]
Oglesby, et al., “Evidence for a C4b Binding Site on the C2b Domain of C2-1,” The Journal of Immunology, 141: 926-931, No. 1, Aug. 1, 1988. [cited by applicant]
Oglesby, et al., “Probing a C4b-Binding Site(s) on C2b with Murine Monoclonal Antibodies,” University of Alabama at Birmingham, Birmingham, AL, no date available. [cited by applicant]
Oglesby, et al., “Radioassays for Quantitation of Intact Complement Proteins C2 and B in Human Serum,” Journal of Immunological Methods, 110: 55-62, 1988. [cited by applicant]
Phongsisay et al., “Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barre syndrome”, Journal of Neuroimmunology, 2008, 205: 101-104. [cited by applicant]
Piepers et al., “IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN”, Journal of Neuroimmunology, 2016, 229: 256-262. [cited by applicant]
Rabia et al., “Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility”, Biochemical Engineering Journal, vol. 137, pp. 365-374, Jun. 5, 2018. [cited by applicant]
Ricklin, et al., “Complement-targeted Therapeutics,” Nature Biotechnology, vol. 25, No. 11, Nov. 2007. [cited by applicant]
Ruddy et al., “Hereditary deficiency of the second component of complement (C2) in man: correlation of C2 haemolytic activity with immunochemical measurements of C2 protein”, Immunology, Jun. 1970, 18(6): 943-954. [cited by applicant]
Rudikoff, S. et al., “Single Amino Acid Substitution Altering Antigen-Binding Specificity,” Proc. Natl. Acad. Sci. USA, vol. 79, pp. 1979-1983, Mar. 1982. [cited by applicant]
Spirig et al. “rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcyRs”, J Immunol, Apr. 15, 2018, 200(8): 2542-2553. [cited by applicant]
Stenbaek, E.I., et al., “Human Complement Component C2: Production and Characterization of Polyclonal and Monoclonal Antibodies Against C2,” Molecular Immunology, Pergamon, GB, vol. 23, No. 8, pp. 879-886, Aug. 1, 1986. [cited by applicant]
Wong, et al., “Structural Requirements for a Specificity Switch and for Maintenance of Affinity using Mutational Analysis of a Phage-Displayed Anti-Arsonate Antibody of Fab Heavy Chain First Complementarity-Determining … [cited by applicant]
Wu et al., “Structure-based engineering of a monoclonal antibody for improved solubility”, Protein Engineering, Design and Selection, vol. 23, No. 8, pp. 643-651, Jun. 11, 2010. [cited by applicant]
Xu, et al., “Contribution of the Complement Control Protein Modules of C2 in C4b Binding Assessed by Analysis of C2/Factor B Chimeras,” The Journal of Immunology, 158: 5958-5965, 1997. [cited by applicant]